RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
2017-01-01 Passamonti, F; Giorgino, T; Mora, B; Guglielmelli, P; Rumi, E; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, J. J; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, R. T; Benevolo, G; Albano, F; Caramazza, D; Merli, M; Pietra, D; Casalone, R; Rotunno, G; Barbui, T; Cazzola, M; Vannucchi, A. M.
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
2008-01-01 Passamonti, Francesco; Rumi, E; Caramella, M; Elena, C; Arcaini, L; Boveri, E; Del Curto, C; Pietra, D; Vanelli, L; Bernasconi, P; Pascutto, C; Cazzola, M; Morra, E; Lazzarino, M.
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
2010-01-01 Passamonti, Francesco; Cervantes, F; Vannucchi, Am; Morra, E; Rumi, E; Pereira, A; Guglielmelli, P; Pungolino, E; Caramella, M; Maffioli, M; Pascutto, C; Lazzarino, M; Cazzola, M; Tefferi, A.
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!
2019-01-01 Merli, Michele; Passamonti, Francesco
A gain-of-function mutation of JAK2 in myeloproliferative disorders
2005-01-01 Kralovics, R; Passamonti, Francesco; Buser, As; Teo, Ss; Tiedt, R; Passweg, Jr; Tichelli, A; Cazzola, M; Skoda, Rc
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients
2007-01-01 Brazzelli, V; Prestinari, F; Barbagallo, T; Rona, C; Orlandi, E; Passamonti, Francesco; Locatelli, F; Zecca, M; Villani, S; Borroni, G.
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion
2017-01-01 Pessina, Chiara; Basilico, Claudia; Genoni, Angelo; Meroni, Emanuela; Elli, Lorenzo; Granata, Paola; Righi, Rossana; Pallotti, Francesco; Mora, Barbara; Ferrario, Andrea; Passamonti, Francesco; Casalone, Rosario
A novel germline JAK2 mutation in familial myeloproliferative neoplasms
2014-01-01 Rumi, E.; Harutyunyan, A. S.; Casetti, I.; Pietra, D.; Nivarthi, H.; Moriggl, R.; Cleary, C.; Bagienski, K.; Astori, C.; Bellini, M.; Berg, T.; Passamonti, Francesco; Kralovics, R.; Cazzola, M.
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
2014-01-01 Verstovsek, S.; Passamonti, Francesco; Rambaldi, A.; Barosi, G.; Rosen, P. J.; Rumi, E.; Gattoni, E.; Pieri, L.; Guglielmelli, P.; Elena, C.; He, S.; Contel, N.; Mookerjee, B.; Sandor, V.; Cazzola, M.; Kantarjian, H. M.; Barbui, T.; Vannucchi, A. M.
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
2018-01-01 Couban, Stephen; Benevolo, Giulia; Donnellan, William; Cultrera, Jennifer; Koschmieder, Steffen; Verstovsek, Srdan; Hooper, Gregory; Hertig, Christian; Tandon, Maneesh; Dimier, Natalie; Malhi, Vikram; Passamonti, Francesco
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis | 1-gen-2017 | Passamonti, F; Giorgino, T; Mora, B; Guglielmelli, P; Rumi, E; Maffioli, M; Rambaldi, A; Caramella, M; Komrokji, R; Gotlib, J; Kiladjian, J. J; Cervantes, F; Devos, T; Palandri, F; De Stefano, V; Ruggeri, M; Silver, R. T; Benevolo, G; Albano, F; Caramazza, D; Merli, M; Pietra, D; Casalone, R; Rotunno, G; Barbui, T; Cazzola, M; Vannucchi, A. M. | |
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis | 1-gen-2008 | Passamonti, Francesco; Rumi, E; Caramella, M; Elena, C; Arcaini, L; Boveri, E; Del Curto, C; Pietra, D; Vanelli, L; Bernasconi, P; Pascutto, C; Cazzola, M; Morra, E; Lazzarino, M. | |
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) | 1-gen-2010 | Passamonti, Francesco; Cervantes, F; Vannucchi, Am; Morra, E; Rumi, E; Pereira, A; Guglielmelli, P; Pungolino, E; Caramella, M; Maffioli, M; Pascutto, C; Lazzarino, M; Cazzola, M; Tefferi, A. | |
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good! | 1-gen-2019 | Merli, Michele; Passamonti, Francesco | |
A gain-of-function mutation of JAK2 in myeloproliferative disorders | 1-gen-2005 | Kralovics, R; Passamonti, Francesco; Buser, As; Teo, Ss; Tiedt, R; Passweg, Jr; Tichelli, A; Cazzola, M; Skoda, Rc | |
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients | 1-gen-2007 | Brazzelli, V; Prestinari, F; Barbagallo, T; Rona, C; Orlandi, E; Passamonti, Francesco; Locatelli, F; Zecca, M; Villani, S; Borroni, G. | |
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion | 1-gen-2017 | Pessina, Chiara; Basilico, Claudia; Genoni, Angelo; Meroni, Emanuela; Elli, Lorenzo; Granata, Paola; Righi, Rossana; Pallotti, Francesco; Mora, Barbara; Ferrario, Andrea; Passamonti, Francesco; Casalone, Rosario | |
A novel germline JAK2 mutation in familial myeloproliferative neoplasms | 1-gen-2014 | Rumi, E.; Harutyunyan, A. S.; Casetti, I.; Pietra, D.; Nivarthi, H.; Moriggl, R.; Cleary, C.; Bagienski, K.; Astori, C.; Bellini, M.; Berg, T.; Passamonti, Francesco; Kralovics, R.; Cazzola, M. | |
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea | 1-gen-2014 | Verstovsek, S.; Passamonti, Francesco; Rambaldi, A.; Barosi, G.; Rosen, P. J.; Rumi, E.; Gattoni, E.; Pieri, L.; Guglielmelli, P.; Elena, C.; He, S.; Contel, N.; Mookerjee, B.; Sandor, V.; Cazzola, M.; Kantarjian, H. M.; Barbui, T.; Vannucchi, A. M. | |
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis | 1-gen-2018 | Couban, Stephen; Benevolo, Giulia; Donnellan, William; Cultrera, Jennifer; Koschmieder, Steffen; Verstovsek, Srdan; Hooper, Gregory; Hertig, Christian; Tandon, Maneesh; Dimier, Natalie; Malhi, Vikram; Passamonti, Francesco |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- Articoli su Riviste 277
- Articoli su Riviste::Articolo su ... 277
Data di pubblicazione
- 2020 - 2023 51
- 2010 - 2019 150
- 2000 - 2009 73
- 1998 - 1999 3
Editore
- American Society of Hematology 1
- Blackwell Publishing Ltd 1
- BMC 1
- TAYLOR & FRANCIS LTD 1
Rivista
- BLOOD 41
- LEUKEMIA 31
- HAEMATOLOGICA 23
- AMERICAN JOURNAL OF HEMATOLOGY 18
- BRITISH JOURNAL OF HAEMATOLOGY 14
- JOURNAL OF CLINICAL ONCOLOGY 12
- LEUKEMIA & LYMPHOMA 8
- LEUKEMIA RESEARCH 8
- BLOOD ADVANCES 7
- CANCER 5
Keyword
- Hematology 38
- Humans 34
- myelofibrosis 28
- Female 24
- Male 23
- Middle Aged 23
- JAK2 22
- Aged 20
- Adult 17
- Cancer Research 17
Lingua
- eng 265
- ita 3
Accesso al fulltext
- no fulltext 256
- open 15
- reserved 6